Targeting αvβ8 Integrin with Monoclonal Antibody MEDI8367 Prevents Fibrosis in Preclinical Models of CKD
Kidney360 · 2025
DOI: 10.34067/kid.0000001006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney360, 2025. Verfasst von Elena Liarte Marin und 12 weiteren Autor:innen. Beteiligte Einrichtung: Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Antibodies, Monoclonal, Diabetic Nephropathies. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca.
Abstract (Originalsprache)
Background
CKD is a global health issue exacerbated by the rising prevalence of diabetes and obesity. Renal fibrosis, characterized by the accumulation of extracellular matrix proteins, is a critical factor in CKD progression. Transforming growth factor β (TGF-β), a key profibrotic cytokine, plays a pivotal role in this process. However, systemic inhibition of TGF-β has been limited by associated toxicities.
Methods
This study explores the role of αvβ8 integrin in renal fibrosis and its potential as a therapeutic target in CKD. We used various preclinical models of CKD, including humanized αvβ8 mice and the db/db uninephrectomy model, to investigate the role of αvβ8 integrin in renal fibrosis. Gene Set Variation Analysis (GSVA) was employed to assess fibrotic gene signatures in human kidney biopsies. The therapeutic potential of MEDI8367, a monoclonal antibody targeting αvβ8 integrin, was evaluated in vitro and in vivo .
Results
Our findings demonstrate that αvβ8 integrin is upregulated in the tubulointerstitium of CKD kidneys, particularly in diabetic kidney disease (DKD), and correlates with TGF-β activation and renal function decline. MEDI8367 effectively inhibited αvβ8-mediated TGF-β activation in vitro and attenuated murine unilateral ureteral obstruction (UUO)-induced renal fibrosis. Notably, inhibition of αvβ8 reduced kidney damage and improved kidney function in models of DKD and hypertensive nephropathy.
Conclusions
Our study highlights the potential of MEDI8367 to mitigate renal fibrosis and improve kidney function, offering a novel approach to CKD treatment that complements existing therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca.
- Bioinformatics, Oncology R&D, AstraZeneca.
- Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca.
- Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca.
ORCID-Profile: Elena Liarte Marin, David Baker, James Conway, Jean-Martin Lapointe, Richard Stebbings, Barbara Hebeis, Sonja Hess, Kevin J Woollard
Förderung
- AstraZeneca
Zitieren
APA
Liarte Marin, E., Seth, A., Liang, L., Baker, D., Conway, J., McCarthy, M., Lapointe, J. M., Stebbings, R., Hebeis, B., Hess, S., Hansen, P. B. L., Mulay, S. R., & Woollard, K. J. (2025). Targeting αvβ8 Integrin with Monoclonal Antibody MEDI8367 Prevents Fibrosis in Preclinical Models of CKD. Kidney360. https://doi.org/10.34067/kid.0000001006
Vancouver
Liarte Marin E, Seth A, Liang L, Baker D, Conway J, McCarthy M, et al. Targeting αvβ8 Integrin with Monoclonal Antibody MEDI8367 Prevents Fibrosis in Preclinical Models of CKD. Kidney360. 2025. doi:10.34067/kid.0000001006
BibTeX
@article{LiarteMarin2025,
author = {Liarte Marin, Elena and Seth, Asha and Liang, Lihuan and Baker, David and Conway, James and McCarthy, Michael and Lapointe, Jean-Martin and Stebbings, Richard and Hebeis, Barbara and Hess, Sonja and Hansen, Pernille B L and Mulay, Shrikant R and Woollard, Kevin J},
title = {Targeting αvβ8 Integrin with Monoclonal Antibody MEDI8367 Prevents Fibrosis in Preclinical Models of CKD},
journal = {Kidney360},
year = {2025},
doi = {10.34067/kid.0000001006}
}
EUVIMED